Orgenesis Stock Insiders

ORGS -  USA Stock  

USD 4.78  0.13  2.65%

Orgenesis employes about 111 people. The company is managed by 11 executives with total tenure of roughly 78 years, averaging almost 7.0 years of service per executive having 10.09 employees per reported executive. Discussion of Orgenesis management performance can provide insight into the enterprise performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Orgenesis future performance.
Please check Your Equity Center.

Search Insiders 

 
Refresh
  Scott Carmer  CEO
CEO of Orgenesis Maryland Inc
  Vered Caplan  Chairman
Chairman of the Board, Interim President and CEO

Orgenesis Management Team Effectiveness

Orgenesis has return on total asset (ROA) of (52.72) % which means that it has lost $52.72 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (122.25) %, meaning that it created substantial loss on money invested by shareholders. Orgenesis management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.

Orgenesis Workforce Comparison

Orgenesis is rated below average in number of employees category among related companies. The total workforce of Biotechnology industry is now estimated at about 28,549. Orgenesis adds roughly 111 in number of employees claiming only tiny portion of stocks in Biotechnology industry.

Orgenesis Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Orgenesis insiders, such as employees or executives, is commonly permitted as long as it does not rely on Orgenesis' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Orgenesis insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Orgenesis Benchmark Summation

Operator
The output start index for this execution was zero with a total number of output elements of sixty-one. Orgenesis Price Series Summation is a cross summation of Orgenesis price series and its benchmark/peer. View also all equity analysis or get more info about price series summation math operators indicator.

Orgenesis Notable Stakeholders

An Orgenesis stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Orgenesis often face trade-offs trying to please all of them. Orgenesis' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Orgenesis' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Scott Carmer - CEO of Orgenesis Maryland IncProfile
Vered Caplan - Chairman of the Board, Interim President and CEOProfile
Neil Reithinger - CFO, Treasurer and SecretaryProfile
David Sidransky - DirectorProfile
Yaron Adler - DirectorProfile
Marie Bouillez - DirectorProfile
Etti Hanochi - DirectorProfile
Hugues Bultot - DirectorProfile
Guy Yachin - DirectorProfile
Chris Buyse - DirectorProfile
Sarah Ferber - Chief Scientific OfficerProfile

About Orgenesis Management Performance

The success or failure of an entity such as Orgenesis often depends on how effective the management is. Orgenesis management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Orgenesis management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Orgenesis management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Orgenesis Inc., a biotech company, focusing on cell and gene therapies . The company was incorporated in 2008 and is based in Germantown, Maryland. Orgenesis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 111 people.
The data published in Orgenesis' official financial statements usually reflect Orgenesis' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Orgenesis. For example, before you start analyzing numbers published by Orgenesis accountants, it's critical to develop an understanding of what Orgenesis' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Orgenesis' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Orgenesis' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Orgenesis' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Orgenesis. Please utilize our Beneish M Score to check the likelihood of Orgenesis' management to manipulate its earnings.

Orgenesis Workforce Analysis

Traditionally, organizations such as Orgenesis use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Orgenesis within its industry.

Orgenesis Manpower Efficiency

Return on Orgenesis Manpower

Revenue Per Employee136.6 K
Revenue Per Executive1.4 M
Net Loss Per Employee749.3 K
Net Loss Per Executive7.6 M
Please check Your Equity Center. Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.

Complementary Tools for Orgenesis Stock analysis

When running Orgenesis price analysis, check to measure Orgenesis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orgenesis is operating at the current time. Most of Orgenesis' value examination focuses on studying past and present price action to predict the probability of Orgenesis' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Orgenesis' price. Additionally, you may evaluate how the addition of Orgenesis to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
The market value of Orgenesis is measured differently than its book value, which is the value of Orgenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Orgenesis' value that differs from its market value or its book value, called intrinsic value, which is Orgenesis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orgenesis' market value can be influenced by many factors that don't directly affect Orgenesis underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orgenesis' value and its price as these two are different measures arrived at by different means. Investors typically determine Orgenesis value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orgenesis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.